Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.
暂无分享,去创建一个
D. Bangsberg | A. Moss | J. Hahn | E. Charlebois | D. Guzman | R. Clark | S. Perry
[1] D. Bangsberg,et al. HIV seroprevalence among homeless and marginally housed adults in San Francisco. , 2004, American journal of public health.
[2] A. d’Arminio Monforte,et al. Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity , 2003, Neurology.
[3] A. Zolopa,et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations , 2003, AIDS.
[4] Jerome H. Carter,et al. Duration of highly active antiretroviral therapy regimens. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] F. Mulcahy,et al. Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users , 2003, HIV medicine.
[6] C. Hinkin,et al. Medication adherence among HIV+ adults , 2002, Neurology.
[7] A. Wu,et al. Depression Is a Risk Factor for Suboptimal Adherence to Highly Active Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.
[8] J. Chmiel,et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients , 2002, AIDS.
[9] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[10] D. Vlahov,et al. A PROSPECTIVE STUDY OF ADHERENCE AND VIRAL LOAD IN A LARGE MULTI-CENTER COHORT OF HIV-INFECTED WOMEN , 2002, AIDS.
[11] B. Yip,et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up , 2002, AIDS.
[12] D. Bangsberg,et al. Emergency department use among the homeless and marginally housed: results from a community-based study. , 2002, American journal of public health.
[13] R. Grant,et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. , 2002 .
[14] M. Chesney,et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] John A. Bartlett,et al. Addressing the Challenges of Adherence , 2002, Journal of acquired immune deficiency syndromes.
[16] Marilyn M. Wagener,et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection (vol 133, pg 21, 2000) , 2002 .
[17] Sundhiya Mandalia,et al. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome , 2002, AIDS.
[18] W. Bilker,et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.
[19] R. Grant,et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] F. Hecht,et al. Comparing Objective Measures of Adherence to HIV Antiretroviral Therapy: Electronic Medication Monitors and Unannounced Pill Counts , 2001, AIDS and Behavior.
[21] D. Nicolau,et al. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] R. Steketee,et al. HIV in the United States at the turn of the century: an epidemic in transition. , 2001, American journal of public health.
[23] A. Zolopa,et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. , 2001, AIDS.
[24] D. Bangsberg,et al. Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. , 2001, The American journal of medicine.
[25] J. Hackman,et al. A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. , 2001, The American journal of medicine.
[26] R. Hays,et al. A Comparison Study of Multiple Measures of Adherence to HIV Protease Inhibitors , 2001, Annals of Internal Medicine.
[27] D. Vlahov,et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. , 2001, JAMA.
[28] J. Fleishman,et al. Prevalence and Predictors of Highly Active Antiretroviral Therapy Use in Patients With HIV Infection in the United States , 2000 .
[29] J. Fleishman,et al. Prevalence and Predictors of Highly Active Antiretroviral Therapy Use in Persons with HIV Infection in the U.S , 2000 .
[30] M. Dimatteo,et al. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. , 2000, Archives of internal medicine.
[31] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[32] D. Richman,et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. , 2000 .
[33] M. Chesney,et al. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. , 2000, Archives of internal medicine.
[34] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[35] J. Moatti,et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment , 2000, AIDS.
[36] H. Wineberg. Oregon's Death with Dignity Act: fourteen months and counting. , 2000, Archives of internal medicine.
[37] P. Volberding,et al. Adherence communication: a qualitative analysis of physician-patient dialogue. , 1999, AIDS.
[38] J E Ware,et al. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. , 1998, Journal of clinical epidemiology.
[39] B. Yip,et al. Barriers to use of free antiretroviral therapy in injection drug users. , 1998, JAMA.
[40] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[41] J. Kahn,et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.
[42] T. Wall,et al. Medication adherence strategies for drug abusers with HIV/AIDS. , 1998, AIDS care.
[43] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[44] F. Hecht,et al. Protease inhibitors in the homeless. , 1997, JAMA.
[45] T. Frieden,et al. Tuberculosis in New York City--turning the tide. , 1995, The New England journal of medicine.
[46] A. Zolopa,et al. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. , 1994, JAMA.
[47] R. Chaisson,et al. Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.
[48] P. Koegel,et al. Methodology for Obtaining a Representative Sample of Homeless Persons , 1988 .
[49] Rachel U Lee,et al. Third regional audit of antiretroviral prescribing in HIV patients. , 2003, International journal of STD & AIDS.
[50] R. Grant,et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users , 2002, Journal of General Internal Medicine.
[51] A. Beck,et al. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation , 1988 .